VERU INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
VERU INC. (VERU) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $12.74 million as of 2025-09-30, per its 10-K filed 2025-12-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-12-17
- 2025-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $12.74M.
- 2024-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $10.20M.
- 2023-09-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.90M.
- 2023-06-30: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.93M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-09-30 | $12.74M 10-K · filed 2025-12-17 |
| 2024-09-30 | $10.20M 10-K · filed 2025-12-17 |
| 2023-09-30 | $7.90M 10-K · filed 2024-12-16 |
| 2023-06-30 | $6.93M 10-Q/A · filed 2023-11-15 |
| 2023-03-31 | $5.98M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $5.20M 10-Q · filed 2023-02-09 |
| 2022-09-30 | $4.33M 10-K/A · filed 2024-04-01 |
| 2022-06-30 | $3.50M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.87M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.42M 10-Q · filed 2022-02-09 |
| 2021-09-30 | $2.07M 10-Q · filed 2022-08-11 |
| 2021-06-30 | $770.60K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $574.70K 10-Q · filed 2021-05-12 |
| 2020-12-31 | $1.01M 10-Q · filed 2021-02-10 |
| 2020-09-30 | $1.26M 10-Q · filed 2021-08-12 |
| 2020-06-30 | $1.12M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $1.01M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $928.68K 10-Q · filed 2020-02-12 |
| 2019-09-30 | $804.38K 10-Q · filed 2020-08-13 |
| 2019-06-30 | $843.47K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $759.88K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $670.54K 10-Q · filed 2019-02-13 |
| 2018-09-30 | $622.44K 10-Q · filed 2019-08-08 |
| 2018-06-30 | $487.00K 10-Q · filed 2018-08-14 |
| 2018-03-31 | $456.00K 10-Q · filed 2018-05-11 |
| 2017-12-31 | $335.00K 10-Q · filed 2018-02-14 |
| 2017-09-30 | $447.00K 10-K · filed 2018-12-13 |
| 2017-06-30 | $127.40K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $92.44K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $51.30K 10-Q · filed 2017-02-09 |
| 2016-09-30 | $101.00K 10-K · filed 2018-01-02 |
| 2015-09-30 | $128.00K 10-K · filed 2016-12-12 |
| 2014-09-30 | $204.00K 10-K · filed 2015-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |